在患有多重系统性缩的患者中,利沃多巴诱导的运动障碍的早期发作
Shohei Okusa1,2, Jin Nakahara1,2, Morinobu Seki1,2
1Department of Neurology, Keio University School of Medicine, Japan.
Internal medicine (Tokyo, Japan)
|February 4, 2024
概括
多重系统缩 (MSA) 患者可能会患上勒沃多巴诱导的运动障碍症 (LID). 这一案例突出显示了MSA患者独特的LID呈现,即使利沃多巴反应有限.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 运动障碍 运动障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 多重系统缩 (MSA) 是一种罕见的神经退行性疾病.
- MSA呈现出帕金森症,动力衰竭和自主功能障碍.
- 列沃多巴诱导的动力障碍 (LID) 可能发生在MSA患者中,虽然比帕金森病更少.
研究的目的:
- 在患有多重系统缩 (MSA) 的患者中报告一种独特的Levodopa诱导的运动障碍病例 (LID).
- 描述LID发病和表现的独特特征在这个MSA病例中.
主要方法:
- 一个50岁的女性被诊断出患有MSA-帕金森症的病例报告.
- 列沃多巴治疗的观察和随后的运动障碍的发展.
主要成果:
- 患者在开始服用利沃多巴治疗10个月后出现了单边下肢动力障碍症.
- 尽管勒沃多巴反应不佳,但功能障碍的分布,时间和发生值得注意.
结论:
- 莱沃多巴诱导的运动障碍症可以在多个系统缩患者中独特地表现出来.
- 这一案例强调了在MSA中考虑非典型的LID呈现的重要性.
相关概念视频
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Parkinson's Disease: Overview
547
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
547
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
323
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
323
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K


